TransMedics Group (NASDAQ:TMDX) and Competitive Technologies (OTCMKTS:CTTC) Head to Head Review

Competitive Technologies (OTCMKTS:CTTC) and TransMedics Group (NASDAQ:TMDX) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, risk, institutional ownership, dividends, profitability, valuation and analyst recommendations.

Analyst Recommendations

This is a breakdown of recent ratings and recommmendations for Competitive Technologies and TransMedics Group, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Competitive Technologies	0	0	0	0	0.00
TransMedics Group	0	4	6	0	2.60

TransMedics Group has a consensus price target of $144.25, indicating a potential upside of 11.52%. Given TransMedics Group’s stronger consensus rating and higher probable upside, analysts clearly believe TransMedics Group is more favorable than Competitive Technologies.

Earnings and Valuation

This table compares Competitive Technologies and TransMedics Group”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Competitive Technologies	N/A	N/A	N/A	N/A	N/A
TransMedics Group	$566.35 million	7.81	$35.46 million	$2.47	52.37

TransMedics Group has higher revenue and earnings than Competitive Technologies.

Insider and Institutional Ownership

99.7% of TransMedics Group shares are owned by institutional investors. 17.5% of Competitive Technologies shares are owned by insiders. Comparatively, 7.0% of TransMedics Group shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Profitability

This table compares Competitive Technologies and TransMedics Group’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Competitive Technologies	N/A	N/A	N/A
TransMedics Group	16.20%	31.42%	10.55%

Summary

TransMedics Group beats Competitive Technologies on 8 of the 9 factors compared between the two stocks.

About Competitive Technologies

Calmare Therapeutics Incorporated, a medical device company, develops and commercializes products and technologies for chronic neuropathic pain and wound care affliction patients in the United States. Its flagship medical device is Calmare Pain Therapy Device, a non-invasive and non-addictive modality for the treatment of chronic and neuropathic pain. The company was formerly known as Competitive Technologies, Inc. and changed its name to Calmare Therapeutics Incorporated in August 2014. Calmare Therapeutics Incorporated was founded in 1968 and is based in Fairfield, Connecticut.

About TransMedics Group

TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its OCS includes OCS LUNG for the preservation of standard criteria donor lungs for double-lung transplantation; OCS Heart, a technology for preservation of DBD donor hearts deemed unsuitable due to limitations of cold storage and for ex vivo reanimation, functional monitoring, and beating-heart preservation of donation-after-circulatory-death hearts; and OCS Liver for the preservation of DBD and DCD of donor livers. The company also developed national OCS program, a turnkey solution for outsourced organ retrieval; and provides OCS organ management and logistics services, including aviation and ground transportation, and other coordination activity. The company was founded in 1998 and is headquartered in Andover, Massachusetts.